Saama vs Unlearn.AI (2026)
Two very different applications of models to clinical development. Unlearn generates digital twins of trial participants, forecasting how an individual would have progressed under control, and uses that as a covariate to reduce the number of patients a trial needs. Its method transparency approaches an academic standard and its regulatory position is arguably a harder achievement than a device clearance and unique in this index. Saama automates the data operations layer, cleaning, reconciling and reviewing trial data across more than fifteen hundred studies, and it names its own agent autonomy level. They solve different problems: one changes the design of the trial, the other processes what the trial produces. Unlearn's evidence measures statistical efficiency rather than patient outcomes, which is exactly the right claim and should not be over read.
- The method transparency approaches an academic standard, with the procedure published and the statistical properties described rather than asserted.
- Its regulatory achievement is distinct and arguably harder than a device clearance, and it is unique in this index.
- The autonomy question is solved by design rather than by policy, which is the most rigorous answer to it recorded here.
- It automates the data operations layer beneath drug development, cleaning, reconciling, reviewing and reporting the trial data on which submissions depend.
- Deployment is substantial and long standing across more than fifteen hundred studies at over fifty sponsors, and it names its own autonomy level for its agents.
- For a sponsor whose timelines slip in data management rather than in design, that is the binding constraint.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Saama and Unlearn.AI are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Saama | Unlearn.AI |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Trials AI |
| Founded | Not recorded | 2017 |
| Headquarters | Campbell, California | San Francisco, California, United States |
| Website | saama.com | unlearn.ai |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Saama its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Clinical and Operational Evidence. Set against Unlearn.AI, Saama grades higher on Clinical and Operational Evidence, HIPAA and BAA Posture and Setting and Specialty Coverage. Its thinnest published disclosure sits on Model Supply Chain Disclosure and AI Liability and Recourse. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards Unlearn.AI its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against Saama, Unlearn.AI grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and FDA and Regulatory Status. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Saama or Unlearn.AI?
On the axes where the AI Health Index separates them, Saama grades higher on Clinical and Operational Evidence, HIPAA and BAA Posture and Setting and Specialty Coverage, and Unlearn.AI grades higher on several axes, including Model and Technology Transparency, Model Supply Chain Disclosure and FDA and Regulatory Status. Unlearn.AI leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do Saama and Unlearn.AI differ most?
The widest separation the AI Health Index records between Saama and Unlearn.AI is on Setting and Specialty Coverage, where Saama grades A and Unlearn.AI grades C. That axis sits in the Commercial group, so it should carry the most weight for a buyer whose binding constraint is contracting, scope and what the price actually covers.
Where do Saama and Unlearn.AI grade the same?
The AI Health Index grades Saama and Unlearn.AI the same on several axes, including AI Centrality, Autonomy and Oversight Model and AI Safety and PHI Stewardship. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
What have Saama and Unlearn.AI not disclosed?
At the last review, at least one of Saama and Unlearn.AI published thin or absent detail on Model Supply Chain Disclosure and AI Liability and Recourse. The AI Health Index treats an absent disclosure as a gap in the public record rather than a failure of the product, so these are the axes to get in writing during diligence instead of inferring from the grade.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Trials AI page.
These operate at different points and are complementary rather than competing: one changes the statistical design of a trial before it runs, the other processes the data once it does. Unlearn's evidence measures statistical efficiency rather than patient outcomes, which is the right claim for what it does but should not be read as clinical benefit. Neither publishes an independent security attestation. Saama publishes a governance framework with nothing measurable behind it. Both should be asked whether one sponsor's data informs models serving another, and the answer belongs in contract.